Search information
OnKure Therapeutics, Inc.
Companies
"Audit"
Keywords
Tables in SEC filings
Source
Director Since | Year Current Term Expires | Current Director Class | Audit Committee | Compensation Committee | Nominating and Corporate Governance Committee | ||||||||||
Roshawn A. Blunt | 2022 | 2025 | I | X | |||||||||||
Eric M. Dube, Ph.D. | 2021 | 2025 | I | X | X | * | |||||||||
Paul W. Hoelscher | 2022 | 2025 | I | X | * | X | |||||||||
Edward T. Mathers | 2017 | 2026 | II | X | * | ||||||||||
Bali Muralidhar, M.D., Ph.D. | 2020 | 2026 | II | X | X | ||||||||||
Stacey D. Seltzer | 2020 | 2026 | II | X | X | ||||||||||
Gregory J. Flesher | 2020 | 2024 | III | ||||||||||||
Michael Grey | 2017 | 2024 | III | ||||||||||||
Niall O’Donnell, Ph.D. | 2017 | 2024 | III |
2023 | 2022 | |||||||
Audit Fees (1) | $ | 613,412 | $ | 571,830 | ||||
All Other Fees (2) | 2,000 | 2,000 | ||||||
Total Fees | $ | 615,412 | $ | 573,830 |